Market Access Agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts (Q34044177)

30 July 2017

3 references

10 January 2024

7 February 2024

Market Access Agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts (English)

1 reference

30 July 2017

Szymon Jarosławski

1

1 reference

PubMed ID

21982545

30 July 2017

Mondher Toumi

series ordinal

2

1 reference

30 July 2017

8 October 2011

3 references

BMC Health Services Research

30 July 2017

10 January 2024

7 February 2024

3 references

30 July 2017

10 January 2024

7 February 2024

11

1 reference

30 July 2017

259

1 reference

Creative Commons Attribution 2.0 Generic

30 July 2017

start time

8 October 2011

3 references

April 2022 Public Data File from Crossref

10 January 2024

April 2022 Public Data File from Crossref

7 February 2024

1 reference

exact match

https://scigraph.springernature.com/pub.10.1186/1472-6963-11-259

0 references

cites work

Reducing uncertainty in value-based pricing using evidence development agreements: the case of continuous intraduodenal infusion of levodopa/carbidopa (Duodopa®) in Sweden

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3203045

Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong?

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3203045

Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3203045

A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3203045

The Multiple Sclerosis Risk Sharing Scheme Monitoring Study--early results and lessons for the future

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3203045

Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers

28 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1472-6963-11-259

Design of patient access schemes in the UK: influence of health technology assessment by the National Institute for Health and Clinical Excellence

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1472-6963-11-259

Risk-sharing agreements for innovative drugs: a new solution to old problems?

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21982545

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Patient access schemes for high-cost cancer medicines

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21982545

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1472-6963-11-259

1 reference

PubMed ID

21982545

Dimensions Publication ID

30 July 2017

0 references

1 reference

30 July 2017

1 reference

PubMed ID

21982545